Lilly
Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company is dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on purpose-built medicines designed to selectively and potently inhibit oncogenic drivers of cancer. We believe that this approach, combined with tumor genomic testing to identify appropriate patients, will allow us to develop medicines that deliver on the promise of precision medicine.